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Abstract: Objective: To have enough information about the prevalence of the ARV side effects in pregnant women 
infected with HIV and their infants and also evaluate drug efficacy in decreasing HIV infection in their children. 
Method: This descriptive study was based on information of 40 pregnant women infected with HIV files at voluntary and 
counseling center, Imam Khomeini Hospital, Tehran, Iran during 2009 -2013. In this study, we evaluated epidemiologic, 
demographic, clinical, laboratory data and drugs side effects,. 
Results: The most commonly used drug group was AZT/3TC/EFV; about 75.5% of patients received mother to child 
prevention and 27.5% received ARV Antiretroviral therapy treatment. 5% anemia, 2.5% rash and 2.5% pre rupture of 
membranes were reported and no preeclampsia or gestational diabetes were reported in patients files. Only one abortion 
(2.5%) was occurred in late first trimester. Except rash, other adverse effects were solely reported in ARV treatment 
group. All neonates had normal Apgar score. Fetal defects were not reported at birth.  
Conclusion: In this evaluation, safety of ARV in pregnancy period and at birth was observed especially in the group 
received prevention of mother to child transmission (PMTCT). So we advise ARV treatment or PMTCT in pregnancy 
period. 
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INTRODUCTION 
After high active antiretroviral therapy (HAART), 
transmission rate of HIV dramatically decreased from 
20-25% to 2% in recent years [1]. According to global 
summary of the AIDS Epidemic reported by WHO, 
number of people living with HIV has been estimated 
more than 35 million [2]. 
Prevalence of HIV among the general population in 
Iran remains low, but it stands at 15.07 percent among 
IV drug users. Measures taken over the past ten years 
have resealed slower progression of the epidemic 
among IV drug users. Nevertheless this group remains 
the most important factor, fueling HIV epidemic in Iran 
[3]. 
The number of women living with HIV has increased 
recently. Base on that there is increased number of 
children being born with HIV in recent years. Although 
the absolute number of these children remains low, 
failure to scale up effective prevention of mother to 
child transmission (PMTCT) programs could prove 
problematic in the future [3]. 
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UNAIDS has articulated 10 specific targets to guide 
collective action until 2015, as an example, to eliminate 
new infections among children and substantially reduce 
the number of mothers dying from AIDS-related causes 
[4]. 
Two main risk factors for transmission have 
consistently been maternal plasma and breast milk viral 
load followed by maternal immunologic status and 
clinical stage. Some associated maternal risk factors 
include low CD4 cell counts, anemia, advanced clinical 
disease stage, mastitis and actual maternal 
seroconversion during pregnancy or breastfeeding [6, 
7]. 
Among infected ARV users infants, about 25 to 40 
percent of infant infections were estimated to occur in 
uterus, 50% around the time of labor/delivery or 
through very early breastfeeding and the remainder 
during the breastfeeding period. A majority of 
transmission from the uterus is thought to occur during 
the third trimester [8]. ARV intervention is the 
cornerstone of strategies to prevent mother to child HIV 
transmission [9]. 
In 2013, WHO recommended the initiation of a 
combination ARV regimen for all HIV – infected 
pregnant or breastfeeding women, regardless of their 
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CD4 cell count. In addition, all infants born to HIV- 
infected mothers should receive post exposure ARV 
prophylaxis [10]. Abundant efforts access ARV for 
prenatal prevention have also brought about a marked 
decrease in prenatal HIV transmission [11]. 
With appropriate ARV prophylaxis, the risk of HIV 
infection for an infant via prenatal transmission is now 
estimated to be less than 2 percent in the United States 
and Europe [12-14]. 
Since enough data about ARV adverse effects or its 
efficacy in pregnant women and their infants do not 
exist; this study was carried out in order to help 
choosing proper decisions to decrease HIV infection in 
children.  
METHOD 
In this descriptive study, we evaluated the files of 
pregnant women infected with HIV referred to Imam 
Khomeini Hospital, Voluntary Counseling and Testing 
Center and their information were documented until 
delivery / labor. 
All patients’ information remained confidential. 
Analysis was conducted by using SPSS17 statistical 
software. There were some defects related to 
registration of laboratory test and patients clinical 
information which were due to patients lacking in 
cooperation to visit their physician regularly. 
RESULTS 
In this study we evaluated 40 files of pregnant 
women infected with HIV. Demographic information 
can be seen in Table 1. Of 5% drug abusers, one of 
them was ice user and another was unknown. Of those 
participants which contracted HIV through sexual 
transmission, all had spouses with HIV positive results. 
In the study site one of criteria for AZT cessation was 
Hb ≤ 7.5 (regarding CDC criteria). 
There was no thrombocytopenia and leucopenia 
observed in one of the cases which was laid under 
ARV treatment pre-pregnancy and leucopenia was 
removed in second trimester. Significant laboratory 
data are shown in Tables 2 and 3 and in Table 4 co-
infections are shown. 
There was no TB or syphilis co-infection; however 4 
patients had received INH prophylaxis due to PPD 
positive result. One patient had diabetes mellitus and 
two had HTN, prior to the current pregnancy. PROM 
and abortion were separately observed in 2.5% (1 case 
for each) in first trimester. 
Table 1: Demographic Characteristics of Participants  
Variable  Frequency Percent 
Age group 
<=25 6 15.00 
26-30 17 42.50 
31-35 12 30.00 
>35 5 12.50 
Education  
Less than/ high school 17 42.50 
Diploma 19 47.50 
Academic 4 10.00 
Job  
Unemployed 32 80.00 
Employed 8 20.00 
Location  
Town  39 97.50 
Village  1 2.50 
Drug abuse  
Yes 2 5.00 
No 38 95.00 
Pregnancy status 
Wanted  25 62.50 
Un-wanted  15 37.50 
Transmission way  
Sexual 27 67.50 
Blood 2 5.00 
Other 11 27.50 
Spouse status  
Infected 34 87.18 
Un infected 5 12.82 
 
Table 2: Mean of Hemoglobin and CD4 among 
Participants  
 Mean Std. Err. [95% Conf. interval] 
Hemoglobin 1 12.19 0.37 11.40, 12.99 
Hemoglobin 2 11.31 0.39 10.47, 12.14 
Hemoglobin 3 12.07 0.29 11.44, 12.70 
CD4 interim 439.25 23.60 391.51, 486.99 
1: First trimester; 2: Second trimester; 3: Third trimester. 
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Table 3: Laboratory Characteristics among Participants  
Variable  Frequency Percent 
HB in Trimester 1 
>7.5 21 52.50 
≤7.5 0 - 
Unknown  19 47.50 
HB in Trimester 2 
>7.5 26 65.00 
≤7.5 0  
Unknown 14 35.00 
HB in Trimester 3 
>7.5 31 77.50 
≤7.5 2 5.00 
Unknown 7 17.00 
CD4 
<200 4 10.00 
200-499 22 55.00 
≥500 14 35.00 
 
Table 4: Prevalence of Co-infection with HCV and HBV 
among Participants 
Variable  Frequency Percent 95% Confidence interval  
HCV 4 10 3.4, 24 
HBV 2 5 0.4, 17.4 
 
All studied women delivered by caesarian section 
(c/s). All neonates had normal routine exam and 
normal Apgar score and fetal defects were not reported 
at birth. HIV prophylaxis was prescribed to all, although 
HIV test results were negative in all of them at birth. 
Drug information and drug groups are showed in 
Tables 5 and 6. 
About 75% of patient received PMTCT and 27.5% 
were lied under ARV treatment. In later group, some 
patients received ARV treatment prior to being referred 
to the study site while other patients were in PMTCT 
group who were then based on clinical and laboratory 
changes, lied in ARV treatment group. 
The common combined ARV regimen used in this 
study was AZT/3TC/EFV (80%) followed by AZT/3TC/ 
Kaletra (10%). Other regimens included AZT/3TC/NVP 
(7.5%) and TDF/3TC/EFV (2.5%). AZT/3TC/NVP group 
was stopped and substituted with TDF/3TC/EFV owing 
to drug resistance in one case. Also drug resistance 
was observed in 2 pregnant women in AZT/3TC/EFV 
group, so EFV was substituted with NVP. Rash and 
drug resistance were induced by EFV and NVP 
respectively, so they were stopped and substituted with 
Kaletra. 
Table 5: Distribution of Type Drugs Consumption 
among Participants 
Variable  Frequency Percent 
ARV 
Treatment  11 27.50 
Prophylaxis  29 72.50 
Drugs  
AZT 39 97.5 
3TC 40 100 
EFV 33 82.50 
KALETRA  4 10.00 
TDF 1 2.50 
NVP 3 7.50 
Drug groups  
AZT, 3TC, EFV 32 80.00 
AZT, 3TC, KALETRA 4 10.00 
AZT, 3TC, NVP 3 7.5 
TDF, 3TC, EFV 1 2.5 
 
Table 6: Prevalence of Side Effect and Drug Resistance 
among Participants 
Variable  Frequency Percent 95% Confidence 
interval  
Side effect  3 7.50 1.57, 20.39 
Drug resistance  4 10 3.4, 23.6 
Type of Drug resistance 
AZT/3TC/NVP 1 2.5 0.00, 14 
AZT/EFV 1 2.5 0.00, 14 
CALETRA 1 2.5 0.00, 14 
NVP 1 2.5 0.00, 14 
 
On the whole, 10% drug replacement was observed 
due to drug resistance. One of the patients under 
AZT/3TC/Kaletra treatment had Hb= 7.1, but the rest in 
that group continued the regimen without any problem 
until labor. In this study, 5% anemia and 2.5% rash 
were occurred. 
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DISCUSSION 
ARV treatment in pregnant women infected with HIV 
involves two separate but related goals: reduction of 
mother to child transmission (MTCT) and treatment of 
maternal HIV diseases. The most important factor to 
decrease MTCT risk can be considered as mother and 
child prophylaxis treatment. 
Early diagnosis and ARV treatment in pregnant 
women infected with HIV and their infants are two 
important factors in reducing HIV transmission among 
them. An important point being discussed in various 
studies is early and late ARV drugs side effects in 
pregnant women and their infants. This issue is 
significant to avoid drug toxicity in the mother and 
fetus. In our study it was considered to mention affair 
and also reported drug resistance. 
In 2013, WHO guidelines recommended the 
initiation of a combination of TNF +3TC (or 
emtricitabine) + EFV in all HIV-infected pregnant or 
breast feeding women. For women who cannot tolerate 
first line regimen, it was recommended to use 
alternative agents AZT to replace TNF and nevirapine 
to replace EFV in the three –drug regimen [10] for the 
subset of HIV-infected women in resource limited 
settings on first line therapy who develop virology, 
clinical failure, omit develop or significant toxicities, and 
also who cannot tolerate the first line regimen, a switch 
should be made to a second –line regimen containing a 
protease inhibitor, such as kaletra [10]. 
In our study, combination regimen was used in all 
patients. AZT /3TC/EFV combination was used in 80% 
of patients based on state guideline (with attention to 
drug availability, cost, resistance, side effects and 
efficacy). 
While 3.8 – 38% of pregnant women in general 
population will develop anemia during pregnancy, 
depending on nutritional status and trimester [15], 
prevalence of anemia was 5% in HIV-infected studied 
women. 
Consistent to our study, in a cohort study in 
Thailand in 2001-2006, among 246 pregnant HIV-
infected women, prevalence of anemia was reported 
5.3% [16].  
In one case with anemia (Hb= 7.1), AZT was 
stopped and substituted with TNF (due to drug 
resistance), however in other cases decrease of Hb 
was only observed for a short period of time, and AZT 
was continued without any problem.  
In this study 2.5% of patients were developed rash 
but significant nausea or vomiting were not reported 
while in the mentioned study in Thailand nausea 
(vomiting) and rash developed 1.2% and 0.4%, 
respectively [16]. 
HBV co-infection is common in many developing 
countries and increases the risk of hepatotoxicity from 
ARV by three to five folds [17]. In a study in Nigeria of 
1564 patients, the risk for serious hepatotoxicity, 24 
weeks after initiation of ARV was 3.1 percent in 
patients co -infected with HBV compared to 0.5% in 
patients with HIV alone; the hepatotoxicity was not 
associated with either baseline HBV DNA 
concentration or HBe Ag status [18]. 
In our study 4 HCV and 2 HBV co-infections were 
observed while one of them had HBV and HCV co-
infection simultaneously, so on the whole, HBV and 
HCV co-infection rate was 12.5%. Despite the fact that 
these patients had received ARV, there was no report 
of hepatotoxicity. Therefore, it is assumed that high 
prevalence of HCV co-infection may be associated with 
infected partner or use of contaminated syringe. 
In this center, in order to decrease HIV 
transmission, recommended delivery method is 
caesarean section [15]. Almost all patients underwent 
C/S and the only exception was the abortion case 
(2.5%) which happened in late first trimester. This case 
was a 41 year old pregnant woman that afflicted with 
diabetes mellitus and HIV prior to this pregnancy. 
Based on many studies up to now, no evidence is 
gained to relate HIV to abortion. 2.5% (1case) showed 
PROM symptoms. However, there was no post-delivery 
infection observed, compared to 8.7% PROM and 
17.4% post-delivery infection in another study in this 
center (2004-2008) [19]. In the pointed study in 
Thailand PROM was 1.6% [16]. 
The overall rate of preeclampsia in the general 
population is 2-8% [20]. Some studies have reported 
higher rates of preeclampsia in the recipient ARV 
women [16]. In our study, gestational HTN was 
reported but no preeclampsia was seen. Approximate 
rate of gestational diabetes in general population is 2-
5%. According to some studies, gestational diabetes in 
ARV recipient women is similar to general population 
but other studies have reported higher rates in HIV-
infected women than general population. 
In consistent with other study showing 5.9-9.2% of 
LBW, no LBW was observed in this study [22]. 
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Inadequate antenatal care for pregnant women might 
be the cause of LBW in other studies. In our study all of 
neonates had normal Apgar score. Fetal defects were 
not reported at birth. The use of ARV during pregnancy 
has generally been found safe in trials to date and the 
benefits for PMTC have been judged to outweigh the 
potential adverse reactions that may occur [9]. Our 
study has also approved the mentioned theory. In this 
study, two important issues were assessed: first, to 
study ARV prophylaxis efficacy in prevention of fetus 
affliction and second, to research on fetus defects rate 
in pregnant HIV infected women who had received 
ARV. ARV safety was observed during pregnancy until 
delivery. Although infants should be followed up 
several months after birth to reach the final goal, our 
efforts can be steps to achieve UNAIDS goals to 
eliminate new infections among children up to 2015.  
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